Supported Interventions
Each compound is given in the diet at the following levels (part per million -ppm- which is defined as milligrams of agent per kilogram of food). All testing is Stage I unless otherwise indicated.
| Compound | Cohort | Concentration in Food | Age at Treatment Initiation | Increase in Median (Med) and Maximum (Max) Lifespan |
|---|---|---|---|---|
| 4-OH-a-phenyl-N-tert-butyl nitrone (4-OH-PBN) | 2004 | 315 ppm | 4 mo | none |
| aspirin (Asp) | 2004 | 20 ppm | 4 mo | Male (Med) |
| nitroflurbiprofen (NFP) | 2004 | 200 ppm | 4 mo | none |
| nordihydroguaiaretic acid (NDGA) | 2004 | 2500 ppm | 9 mo | Male (Med) |
| caffeic acid phenethyl ester (CAPE) | 2005 | 30 ppm | 4 mo | none |
| caffeic acid phenethyl ester (CAPE) | 2005 | 300 ppm | 4 mo | none |
| enalapril (Enal) | 2005 | 120 ppm | 4 mo | none |
| rapamycin (Rapa) | 2005 | 14 ppm | 20 mo | Male (Med, Max) & Female (Med, Max) |
| rapamycin (Rapa) | 2006 | 14 ppm | 9 mo | Male (Med, Max) & Female (Med, Max) |
| resveratrol (Res) | 2006 | 300 ppm | 12 mo | none |
| resveratrol (Res) | 2006 | 1200 ppm | 12 mo | none |
| simvastatin (Sim) | 2006 | 12 ppm | 10 mo | none |
| simvastatin (Sim) | 2006 | 120 ppm | 10 mo | none |
| curcumin (Cur) | 2007 | 2000 ppm | 4 mo | none |
| green tea extract (GTE) | 2007 | 2000 ppm | 4 mo | none |
| medium-chain triglyceride oil (MCTO) | 2007 | 60,000 ppm | 4 mo | none |
| oxaloacetic acid (OAA) | 2007 | 2200 ppm | 4 mo | none |
| resveratrol (Res) | 2007 | 300 ppm | 4 mo | none |
| 17-a-estradiol (17aE2) | 2009 | 4.8 ppm | 10 mo | Male (Med) |
| acarbose (ACA) | 2009 | 1000 ppm | 4 mo | Male (Med, Max) & Female (Med, Max) |
| methylene blue (MB) | 2009 | 28 ppm | 4 mo | none |
| rapamycin (Rapa) - Stage II | 2009 | 4.7 ppm | 9 mo | Female (Med, Max) |
| rapamycin (Rapa) - Stage II | 2009 | 14 ppm | 9 mo | Male (Med, Max) & Female (Med, Max) |
| rapamycin (Rapa) - Stage II | 2009 | 42 ppm | 9 mo | Male (Med, Max) & Female (Med, Max) |
| fish oil (FO) | 2010 | 15,000 ppm | 9 mo | none |
| fish oil (FO) | 2010 | 50,000 ppm | 9 mo | none |
| nordihydroguaiaretic acid (NDGA) - Male only, Stage II | 2010 | 800 ppm | 6 mo | Male (Med) |
| nordihydroguaiaretic acid (NDGA) - Male only, Stage II | 2010 | 2500 ppm | 6 mo | Male (Med) |
| nordihydroguaiaretic acid (NDGA) - Stage II | 2010 | 5000 ppm | 6 mo | Male (Med) |
| 17-a-estradiol (17aE2) | 2011 | 14 ppm | 10 mo | Male (Med, Max) |
| metformin (Met) | 2011 | 1000 ppm | 9 mo | none |
| metformin and rapamycin (MetRapa) | 2011 | Met:1000 ppm and Rapa:14 ppm | 9 mo | Male (Med, Max) & Female (Med, Max) |
| Protandim (Prot) | 2011 | 600 ppm then 1200 ppm | 10 mo then 17 mo | Male (Med) |
| ursodeoxycholic acid (UDCA) | 2011 | 5000 ppm | 5 mo | none |
| 2-(2-Hydroxyphenyl)benzoxazole (HBX) | 2012 | 1 ppm | 15 mo | none |
| acarbose (ACA) | 2012 | 1000 ppm | 16 mo | Male (Med, Max) & Female (Max) |
| INT-767 FXR/TGR5 agonist (INT-767) | 2012 | 180 ppm | 10 mo | none |
| acarbose (ACA) - Stage II | 2013 | 400 ppm | 8 mo | Male (Med, Max) |
| acarbose (ACA) - Stage II | 2013 | 1000 ppm | 8 mo | Male (Med, Max) & Female (Med, Max) |
| acarbose (ACA) - Stage II | 2013 | 2500 ppm | 8 mo | Male (Med, Max) & Female (Med) |
| ursolic acid (UA) | 2013 | 2000 ppm | 10 mo | none |
| aspirin (Asp) | 2014 | 60 ppm | 11 mo | none |
| aspirin (Asp) | 2014 | 200 ppm | 11 mo | none |
| glycine (Gly) | 2014 | 80,000 ppm | 9 mo | none |
| inulin (Inu) | 2014 | 600 ppm | 11 mo | none |
| TM5441 (TM5441) | 2014 | 60 ppm | 11 mo | none |
| 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride (DMAG) | 2015 | 30 ppm | 6 mo | none |
| b-guanidinopropionic acid (bGPA) | 2015 | 3300 ppm | 6 mo | none |
| minocycline (Min) | 2015 | 300 ppm | 6 mo | none |
| MitoQ (MitoQ) | 2015 | 100 ppm | 7 mo | none |
| rapamycin (Rapa) - Stage II | 2015 | 42 ppm | 20 mo (stop at 23) | Male (Med, Max) |
| rapamycin (Rapa) - Intermittent, Stage II | 2015 | 42 ppm (every other month) | 20 mo | Male (Med, Max) & Female (Med, Max) |
| rapamycin (Rapa) - Stage II | 2015 | 42 ppm | 20 mo | Male (Med, Max) & Female (Med, Max) |
| 17-a-estradiol (17aE2) - Stage II | 2016 | 14.4 ppm | 16 or 20 mo | none |
| 3-(3-hydroxybenzyl)-5-methylbenzo[d]oxazol-2(3H)-one (MIF098) | 2016 | 240 ppm | 8 mo | none |
| canagliflozin (Cana) | 2016 | 180 ppm | 7 mo | Male (Med, Max) |
| candesartan cilexetil (CC) | 2016 | 30 ppm | 7 mo | none |
| geranylgeranyl acetone (GGA) | 2016 | 600 ppm | 9 mo | none |
| nicotinamide riboside (NR) | 2016 | 1000 ppm | 8 mo | none |
| Hydrogen Sulfide prodrug SG1002 | 2016 | 240 ppm | 19 mo | none |
| 1,3-butanediol (BD) | 2017 | 100,000 ppm | 6 mo | none |
| Captopril (Capt) | 2017 | 180 ppm | 5 mo | Female (Med); Male Results Indeterminant |
| L-Leucine (Leu) | 2017 | 40,000 ppm | 5 mo | none |
| PB125 | 2017 | 100 ppm | 5 mo | none |
| Sulindac (Sul) | 2017 | 5 ppm | 5 mo | none |
| Syringaresinol (Syr) | 2017 | 300 ppm | 5 mo | none |
| Rapamycin + Acarbose (RaAc) - Stage II | 2017 | Ra: 14.7 ppm and Ac: 1000 ppm | 9 mo or 16 mo | Male (Med, Max) & Female (Med, Max) |
| Fisetin (Fis) | 2018 | 600 ppm | 20 mo | none |
| Fisetin (Fis) - Cycling | 2018 | 600 ppm (3 days on/11 days off) | 20 mo | none |
| Hydrogen Sulfide prodrug SG1002 | 2018 | 240 ppm | 18 mo | none |
| Astaxanthin (Asta) | 2019 | 4000 ppm | 12 mo | In Progress |
| Dimethyl Fumarate (DMF) | 2019 | 120 ppm | 9 mo or 16 mo | In Progress |
| Meclizine (Mec) | 2019 | 800 ppm | 12 mo | In Progress |
| Mycophenolic Acid (MPA) | 2019 | 6.7 ppm | 9 mo | In Progress |
| 4-Phenylbutyrate (PBA) | 2019 | 1000 ppm | 9 mo | In Progress |
| Hydrogen Sulfide prodrug SG1002 | 2019 | 240 ppm | 6 mo | In Progress |
| 16 alpha-hydroxyestradiol | 2020 | 5 ppm | 12 mo | In Progress |
| 2,4-Dinitrophenol (DNP) | 2020 | 3 ppm | 6 mo | In Progress |
| Hydralazine | 2020 | 30 ppm | 6 mo | In Progress |
| Nebivolol | 2020 | 60 ppm | 6 mo | In Progress |
| Sodium Thiosulfate (STS) | 2020 | 10,000 ppm | 6 mo | In Progress |
| Canagliflozin (Cana) - Stage II | 2020 | 180 ppm | 16 mo | In Progress |
| 2BAct (2BA) | 2021 | 30 ppm | 7 mo | In Progress |
| Dichloroacetate (DCA) | 2021 | 30 ppm | 7 mo | In Progress |
| Epicatechin (Epi) | 2021 | 60 ppm | 7 mo | In Progress |
| Forskolin (For) | 2021 | 5 ppm | 7 mo | In Progress |
| Halofuginone (Hal) | 2021 | 0.6 ppm | 7 mo | In Progress |
| MSDC-160 (M160) | 2021 | 300 ppm | 7 mo | In Progress |
Related Content
Get a sneak peek of concepts approved by the National Advisory Council on Aging.
Learn about grants and funding opportunities from NIA.
Find resources and data for researchers from NIA.